AtaiBeckley Inc. Common Stock (ATAI)

Price$4.90

Favorite Metrics

Price vs S&P 500 (26W)-29.73%

Price vs S&P 500 (4W)5.98%

Market Capitalization$1.47B

All Metrics

Book Value / Share (Quarterly)$0.61

P/TBV (Annual)6.78x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)160.99%

Cash Flow / Share (Quarterly)$-0.31

Price vs S&P 500 (YTD)-5.61%

Net Profit Margin (TTM)-16142.02%

EPS (TTM)$-2.30

10-Day Avg Trading Volume4.71M

EPS Excl Extra (TTM)$-2.30

EPS (Annual)$-2.91

ROI (Annual)-297.49%

Net Profit Margin (5Y Avg)-28899.22%

Cash / Share (Quarterly)$0.70

Revenue Growth QoQ (YoY)1772.50%

ROA (Last FY)-225.49%

Revenue Growth TTM (YoY)813.29%

EBITD / Share (TTM)$-2.94

ROE (5Y Avg)-109.07%

Operating Margin (TTM)-15582.27%

Cash Flow / Share (Annual)$-0.31

P/B Ratio6.63x

P/B Ratio (Quarterly)6.70x

Net Income / Employee (Annual)$-7

EV / Revenue (TTM)338.62x

Net Interest Coverage (TTM)-40.12x

ROA (TTM)-287.75%

EPS Incl Extra (Annual)$-2.91

Current Ratio (Annual)11.74x

Quick Ratio (Quarterly)11.56x

3-Month Avg Trading Volume4.33M

52-Week Price Return183.80%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.60

P/S Ratio (Annual)359.48x

Asset Turnover (Annual)0.01x

52-Week High$6.75

Operating Margin (5Y Avg)-29988.13%

EPS Excl Extra (Annual)$-2.91

CapEx CAGR (5Y)182.88%

26-Week Price Return-20.98%

Quick Ratio (Annual)11.56x

13-Week Price Return8.33%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)11.74x

Enterprise Value$1,384.626

Asset Turnover (TTM)0.02x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-16137.17%

Cash / Share (Annual)$0.70

3-Month Return Std Dev72.17%

Net Income / Employee (TTM)$-7

ROE (Last FY)-297.49%

Net Interest Coverage (Annual)-114.81x

EPS Basic Excl Extra (Annual)$-2.91

Receivables Turnover (TTM)0.05x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.30

Receivables Turnover (Annual)0.03x

ROI (TTM)-373.24%

P/S Ratio (TTM)359.48x

Pretax Margin (5Y Avg)-27255.25%

Revenue / Share (Annual)$0.02

Tangible BV / Share (Annual)$0.60

Price vs S&P 500 (52W)148.71%

Year-to-Date Return-1.47%

5-Day Price Return6.33%

EPS Normalized (Annual)$-2.91

ROA (5Y Avg)-84.65%

Net Profit Margin (Annual)-16142.02%

Month-to-Date Return13.84%

Cash Flow / Share (TTM)$-0.41

EBITD / Share (Annual)$-2.93

Operating Margin (Annual)-15582.27%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-103.88%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.30

P/TBV (Quarterly)6.78x

P/B Ratio (Annual)6.70x

Pretax Margin (TTM)-16137.17%

Book Value / Share (Annual)$0.61

Price vs S&P 500 (13W)5.47%

Beta1.62x

Revenue / Share (TTM)$0.01

ROE (TTM)-389.74%

52-Week Low$1.29

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.17

4.21

4.20

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ATAIAtaiBeckley Inc. Common Stock	359.48x	813.29%	—	—	$4.90
LLYEli Lilly & Co.	13.45x	44.70%	83.04%	27.59%	$919.90
JNJJohnson & Johnson	5.82x	7.87%	67.95%	14.90%	$230.69
ABBVABBVIE INC.	5.97x	8.57%	71.62%	-2.88%	$203.71
MRKMerck & Co., Inc.	4.51x	1.31%	78.55%	21.23%	$117.10
AZNAstraZeneca PLC	5.39x	8.63%	81.31%	21.88%	$200.69
NVSNovartis AG	4.87x	8.91%	75.82%	15.26%	$150.99
NVONovo-Nordisk A/S	3.74x	6.43%	80.98%	20.66%	$40.46
ABTAbbott Laboratories	3.71x	6.59%	56.50%	8.20%	$96.00
PFEPfizer Inc.	2.50x	-1.64%	75.81%	-3.51%	$27.52
BMYBristol-Myers Squibb Co.	2.52x	-0.22%	72.63%	—	$59.13

About

AtaiBeckley Inc is a clinical-stage biopharmaceutical company developing novel therapies for psychiatric disorders, with a focus on rapid-acting and convenient treatment options. The company's Phase 2 pipeline includes three candidates: BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression, VLS-01 (DMT buccal film) for treatment-resistant depression and social anxiety disorder, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. These programs address significant unmet medical needs in mental health treatment.